Last reviewed · How we verify
Wood Sugar (XYLOSE)
Wood Sugar (XYLOSE) is a small molecule drug developed by LYNE, which remains under the company's ownership. It belongs to the xylose class and was approved by the FDA in 1987. The commercial status of Wood Sugar is off-patent, with no active Orange Book patents. However, there are no generic manufacturers available. As a result, the drug's availability and pricing may be limited.
At a glance
| Generic name | XYLOSE |
|---|---|
| Sponsor | Lyne |
| Drug class | xylose |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
| First approval | 1987 |
Approved indications
Common side effects
Key clinical trials
- A Study of GlcNAc on Tear Production in NGLY1-CDDG (PHASE2)
- Response to Different Wheat Genotypes in Not-celiac Wheat Sensitivity (NA)
- Bio-markers of Not-celiac Wheat Sensitivity (NA)
- A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors (NA)
- Observational Study on the Safety and Efficacy of the Medical Product Fructosin.
- Small Intestinal Absorption in Patients With Chronic Obstructive Pulmonary Disease and Cor Pulmonale (NA)
- Esophageal Absorption in EoE (NA)
- Beneficial Effect of Xylose Consumption on Postprandial Hyperglycemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |